Aktieanalys

Nanexa: Q1 report - ABG

ABG Sundal Collier Publicerad: 04 May 2023 09:57

No material updates in the Q1 report
NEX-20 Ph 1 study completed by June '23e
Live commentary today at 15:00 CET

Events during the quarter

No material updates were provided in the report. The most relevant event during the quarter was the announcement of the outcome of the first preclinical study with NEX-22, where the results showed a controlled release of liraglutide, with plasma exposure over 28 days vs. ~2 days for liraglutide without the PharmaShell coating. Nanexa mentioned that the results will be confirmed with other preclinical studies while the optimisation of the formulation for a Ph 1 study is done in parallel. The NEX-20 study is proceeding according to plan, with estimated study completion before the end of June. No news on the NEX-18 programme were provided.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/nanexa/Equity-research/2023/5/nanexa---q1-report-/

Nyheter om Nanexa

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!